Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Filgrastim 5Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4Radiotherapy 3Polymerase Chain Reaction 3Paclitaxel 3Cisplatin 3Carboplatin 3Amplified Fragment Length Polymorphism Analysis 3Amifostine 3aflibercept 2Therapeutics 2Itraconazole 2Irinotecan 2Ifosfamide 2Gene Expression Profiling 2Flow Cytometry 2Fentanyl 2Etoposide 2Docetaxel 2tislelizumab 1thymoglobulin 1talazoparib 1spartalizumab 1sargramostim 1motexafin lutetium 1liposomal amphotericin B 1fludarabine 1etoposide phosphate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Fondaparinux × Sarcoma × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡